Acquisition Opportunity Parallel 6 was acquired by PRA Health Sciences in 2017, signaling potential alignment with large bio/pharma program needs and potential access to PRA’s broader client network for cross-sell of mobile enrollment and engagement solutions.

Clinical Enrollment Focus The core offering is mClinical platforms for patient enrollment, engagement, and management of clinical trials, suggesting strong value in faster patient recruitment, improved retention, and streamlined trial workflows for life sciences customers.

Government Usecase GovReach targets government agencies to improve digital efficiency and citizen engagement, presenting a sales path into public sector contracts and health/public service programs needing mobile engagement capabilities.

Growth Signals Recognition as a top eClinical trial management provider in 2017 and ongoing acquisitions indicates a growth trajectory and continuous product expansion opportunities to address evolving regulatory and trial complexity.

FinancialProfile With reported annual revenue in the 1M to 10M range and a mid-sized employee base, Parallel 6 represents a target for mid-market deals, offering scalable SaaS solutions suitable for expanding clinical research organizations seeking cost-effective enrollment tech.